ILM1 📈 Medios - Overview
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A1MMCC8
ILM1: Cancer, Neurology, Autoimmune, Eye, Infection, Hemophilia Medications
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products. Medios AG was founded in 2016 and is headquartered in Berlin, Germany. Web URL: https://www.medios.ag
Additional Sources for ILM1 Stock
ILM1 Stock Overview
| Market Cap in USD | 347m |
| Sector | Healthcare |
| Industry | Medical Distribution |
| GiC Sub-Industry | Health Care Distributors |
| IPO / Inception |
ILM1 Stock Ratings
| Growth 5y | -73.6% |
| Fundamental | 37.2% |
| Dividend | - |
| Rel. Strength Industry | -626 |
| Analysts | - |
| Fair Price Momentum | 10.15 EUR |
| Fair Price DCF | 28.93 EUR |
ILM1 Dividends
No Dividends PaidILM1 Growth Ratios
| Growth Correlation 3m | -77.2% |
| Growth Correlation 12m | -14.9% |
| Growth Correlation 5y | -86.2% |
| CAGR 5y | -16.01% |
| CAGR/Mean DD 5y | -0.43 |
| Sharpe Ratio 12m | -0.30 |
| Alpha | -31.69 |
| Beta | 0.55 |
| Volatility | 36.03% |
| Current Volume | 27k |
| Average Volume 20d | 57.5k |
What is the price of ILM1 stocks?
As of January 15, 2025, the stock is trading at EUR 12.26 with a total of 27,028 shares traded.
Over the past week, the price has changed by -7.67%, over one month by +5.92%, over three months by -15.06% and over the past year by -15.18%.
As of January 15, 2025, the stock is trading at EUR 12.26 with a total of 27,028 shares traded.
Over the past week, the price has changed by -7.67%, over one month by +5.92%, over three months by -15.06% and over the past year by -15.18%.
Is Medios a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Medios (XETRA:ILM1) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.21 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ILM1 as of January 2025 is 10.15. This means that ILM1 is currently overvalued and has a potential downside of -17.21%.
Partly, yes. Based on ValueRay Fundamental Analyses, Medios (XETRA:ILM1) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.21 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ILM1 as of January 2025 is 10.15. This means that ILM1 is currently overvalued and has a potential downside of -17.21%.
Is ILM1 a buy, sell or hold?
Medios has no consensus analysts rating.
Medios has no consensus analysts rating.
What are the forecast for ILM1 stock price target?
According to ValueRays Forecast Model, ILM1 Medios will be worth about 11.1 in January 2026. The stock is currently trading at 12.26. This means that the stock has a potential downside of -9.3%.
According to ValueRays Forecast Model, ILM1 Medios will be worth about 11.1 in January 2026. The stock is currently trading at 12.26. This means that the stock has a potential downside of -9.3%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 28.6 | 133.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 11.1 | -9.3% |